User login
WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us at the annual meeting of the American College of Cardiology, as he provided the lowdown on the potentially game-changing novel class of LDL cholesterol–lowering medications known as PCSK9 inhibitors.
One such agent, evolocumab, was the focus of five highly positive phase III clinical trials presented at ACC 14.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us at the annual meeting of the American College of Cardiology, as he provided the lowdown on the potentially game-changing novel class of LDL cholesterol–lowering medications known as PCSK9 inhibitors.
One such agent, evolocumab, was the focus of five highly positive phase III clinical trials presented at ACC 14.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us at the annual meeting of the American College of Cardiology, as he provided the lowdown on the potentially game-changing novel class of LDL cholesterol–lowering medications known as PCSK9 inhibitors.
One such agent, evolocumab, was the focus of five highly positive phase III clinical trials presented at ACC 14.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT ACC 14
